Calorie Restriction and Matched Weight Loss From Exercise: Independent and Additive Effects on Glucoregulation and the Incretin System in Overweight Women and Men

Edward P Weiss, Stewart G Albert, Dominic N Reeds, Kathleen S Kress, Uthayashanker R Ezekiel, Jennifer L McDaniel, Bruce W Patterson, Samuel Klein, Dennis T Villareal, Edward P Weiss, Stewart G Albert, Dominic N Reeds, Kathleen S Kress, Uthayashanker R Ezekiel, Jennifer L McDaniel, Bruce W Patterson, Samuel Klein, Dennis T Villareal

Abstract

Objective: It is not known whether calorie restriction (CR) has additive benefits to those from exercise (EX)-induced weight loss. We hypothesized that weight loss from CR and EX (CREX) improves insulin sensitivity more than matched weight loss induced by EX or CR alone and that the incretin system may be involved in adaptations to CR.

Research design and methods: Sedentary, overweight men and women (n = 52, 45-65 years of age) were randomized to undergo 6-8% weight loss by using CR, EX, or CREX. Glucose, insulin, C-peptide, insulin sensitivity, and incretin hormones (glucagon-like peptide 1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) were measured during frequently sampled oral glucose tolerance tests (FSOGTTs). Incretin effects on insulin secretion were measured by comparing insulin secretion rates from the FSOGTTs to those from a glycemia-matched glucose infusion.

Results: Despite similar weight losses in all groups, insulin sensitivity index values increased twofold more in the CREX group (2.09 ± 0.35 μM/kg/pM × 100) than in the CR (0.89 ± 0.39 μM/kg/pM × 100) and EX (1.04 ± 0.39 μM/kg/pM × 100) groups. Postprandial GLP-1 concentrations decreased only in the CR group (P = 0.04); GIP concentrations decreased in all groups. Incretin effects on insulin secretion were unchanged.

Conclusions: CR and EX have additive beneficial effects on glucoregulation. Furthermore, the adaptations to CR may involve reductions in postprandial GLP-1 concentrations. These findings underscore the importance of promoting both CR and EX for optimal health. However, because data from participants who withdrew from the study and from those who did not adhere to the intervention were excluded, the results may be limited to individuals who are capable of adhering to a healthy lifestyle intervention.

Trial registration: ClinicalTrials.gov NCT00777621.

© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Figures

Figure 1
Figure 1
Body weight and composition changes (top panel) and measures of intervention compliance (bottom panel). Values are reported as the least squares mean ± SE from ANCOVAs in which the change in the outcome was the dependent variable, study group was the independent variable, and baseline values were the covariate. P values reflect the significance of the overall ANCOVA. When overall ANCOVAs were significant at P ≤ 0.05, post hoc paired comparisons were performed according to the principle of protected F tests and least significant difference tests. *P ≤ 0.05 vs. zero (significance of within-group change). †P ≤ 0.05 vs. CR group. ‡P ≤ 0.05 vs. CREX group.

References

    1. Weiss EP, Racette SB, Villareal DT, et al. .; Washington University School of Medicine CALERIE Group . Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr 2006;84:1033–1042
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. .; Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. Tuomilehto J, Lindström J, Eriksson JG, et al. .; Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350
    1. Gulve EA, Spina RJ. Effect of 7-10 days of cycle ergometer exercise on skeletal muscle GLUT-4 protein content. J Appl Physiol (1985) 1995;79:1562–1566
    1. O’Gorman DJ, Karlsson HK, McQuaid S, et al. . Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. Diabetologia 2006;49:2983–2992
    1. Ross R, Dagnone D, Jones PJ, et al. . Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000;133:92–103
    1. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153–165
    1. González N, Acitores A, Sancho V, Valverde I, Villanueva-Peñacarrillo ML. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 2005;126:203–211
    1. Perea A, Viñambres C, Clemente F, Villanueva-Peñacarrillo ML, Valverde I. GLP-1 (7-36) amide: effects on glucose transport and metabolism in rat adipose tissue. Horm Metab Res 1997;29:417–421
    1. Institute of Medicine Food and Nutrition Board: Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients). Washington, DC, The National Academies Press, 2002
    1. Sallis JF. Seven-day physical activity recall. Med Sci Sports Exerc 1997;29(Suppl. 6):89–103
    1. Dalla Man C, Campioni M, Polonsky KS, et al. . Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of β-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes 2005;54:3265–3273
    1. Stumvoll M, Mitrakou A, Pimenta W, et al. . Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295–301
    1. Gordon BA, Fraser SF, Bird SR, Benson AC. Reproducibility of multiple repeated oral glucose tolerance tests. Diabetes Res Clin Pract 2011;94:e78–e82
    1. Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Diabetologia 2014;57:1781–1788
    1. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–1470
    1. Breda E, Cavaghan MK, Toffolo G, Polonsky KS, Cobelli C. Oral glucose tolerance test minimal model indexes of β-cell function and insulin sensitivity. Diabetes 2001;50:150–158
    1. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368–377
    1. Polonsky KS, Given BD, Hirsch L, et al. . Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1988;81:435–441
    1. American College of Sports Medicine ACSM's Guidelines for Exercise Testing and Prescription. Baltimore, Williams & Wilkins, 2014
    1. American Diabetes Association . Standards of medical care in diabetes—2014. Diabetes Care 2014;37(Suppl. 1):S14–S80
    1. Adam TC, Jocken J, Westerterp-Plantenga MS. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 2005;13:710–716
    1. Adam TC, Lejeune MP, Westerterp-Plantenga MS. Nutrient-stimulated glucagon-like peptide 1 release after body-weight loss and weight maintenance in human subjects. Br J Nutr 2006;95:160–167
    1. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety—effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001;25:1206–1214
    1. Weiss EP, Royer NK, Fisher JS, Holloszy JO, Fontana L. Postprandial plasma incretin hormones in exercise-trained versus untrained subjects. Med Sci Sports Exerc 2014;46:1098–1103
    1. Heden TD, Liu Y, Kearney ML, et al. . Prior exercise and postprandial incretin responses in lean and obese individuals. Med Sci Sports Exerc 2013;45:1897–1905
    1. Solomon TP, Haus JM, Kelly KR, Rocco M, Kashyap SR, Kirwan JP. Improved pancreatic β-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. Diabetes Care 2010;33:1561–1566
    1. Kelly KR, Brooks LM, Solomon TP, Kashyap SR, O’Leary VB, Kirwan JP. The glucose-dependent insulinotropic polypeptide and glucose-stimulated insulin response to exercise training and diet in obesity. Am J Physiol Endocrinol Metab 2009;296:E1269–E1274
    1. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829–835
    1. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585–3596
    1. Laferrère B, Teixeira J, McGinty J, et al. . Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:2479–2485
    1. Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK. Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 2010;95:3309–3317
    1. Bose M, Teixeira J, Olivan B, et al. . Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes 2010;2:47–55
    1. Laferrère B, Heshka S, Wang K, et al. . Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709–1716

Source: PubMed

3
Subskrybuj